




# Improved Survival with Interferon Alpha Maintenance Therapy Following Pleurectomy / Decortication and Radiation for Malignant Pleural Mesothelioma



Robert B. Cameron, M.D.  
Shahriyour Andaz, M.D.  
Michael T. Selch, M.D.  
Michael C. Fishbein, M.D.  
Division of Thoracic Surgery



David Geffen School of Medicine at UCLA



# Mesothelioma: STS 2006

All authors have no conflicts to declare

# Prospective Database

- A computerized, prospective database for all patients evaluated by thoracic surgeons at UCLA was started in 1997
- Malignant pleural mesothelioma patients were captured under diagnostic ICD-9 codes 163.0-163.9
- Data captured prospectively includes, diagnoses, risk factors, imaging, laboratory, procedures, chemotherapy, radiation, symptoms and follow-up data

# Prospective Database

## Study Objectives

- to compare outcomes of pleurectomy/decortication and adjuvant radiation to contemporary radical therapies (EPP; trimodality therapy, etc.)
- to identify additional therapies (if any) that may improve survival in mesothelioma (interferon alpha)

# Mesothelioma: UCLA Approach

## Lung-Sparing Surgery

- Radical parietal pleurectomy ✓
- Complete pulmonary decortication (radical visceral pleurectomy)
- Removal of all pleura/tumor off diaphragm, pericardium, mediastinum, and pulmonary hilum ✓
- Preservation of all tissue planes possible
- Lymph node dissection ✓
- Postoperative radiation therapy ✓
- Novel biologic “maintenance” therapies when available

✓ Indicates also part of EPP